Published in Proc Natl Acad Sci U S A on July 16, 2008
Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature (2012) 3.54
Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med (2016) 3.04
RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration. Nature (2015) 2.41
The prion hypothesis: from biological anomaly to basic regulatory mechanism. Nat Rev Mol Cell Biol (2010) 2.22
Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun (2011) 2.04
Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65
Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathway. Mol Cell Proteomics (2009) 1.52
Crystal structure of human prion protein bound to a therapeutic antibody. Proc Natl Acad Sci U S A (2009) 1.29
Copper-dependent regulation of NMDA receptors by cellular prion protein: implications for neurodegenerative disorders. J Physiol (2012) 1.19
RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet (2011) 1.10
A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. J Biol Chem (2011) 1.07
Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One (2010) 1.04
Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death Dis (2015) 1.02
Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther (2011) 0.99
Prion neurodegeneration: starts and stops at the synapse. Prion (2009) 0.96
Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses. Eur J Hum Genet (2009) 0.96
Mutant PrP suppresses glutamatergic neurotransmission in cerebellar granule neurons by impairing membrane delivery of VGCC α(2)δ-1 Subunit. Neuron (2012) 0.96
Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci U S A (2013) 0.95
A mutant prion protein sensitizes neurons to glutamate-induced excitotoxicity. J Neurosci (2013) 0.95
Genetics of prion diseases. Curr Opin Genet Dev (2013) 0.94
Transcriptomic analysis brings new insight into the biological role of the prion protein during mouse embryogenesis. PLoS One (2011) 0.88
Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory. Neuropathol Appl Neurobiol (2015) 0.88
Prions: generation and spread versus neurotoxicity. J Biol Chem (2014) 0.86
Brain transcriptional stability upon prion protein-encoding gene invalidation in zygotic or adult mouse. BMC Genomics (2010) 0.84
Healthy goats naturally devoid of prion protein. Vet Res (2012) 0.84
Experimental animal model and RNA interference: a promising association for bladder cancer research. World J Urol (2009) 0.84
Overexpression of the Hspa13 (Stch) gene reduces prion disease incubation time in mice. Proc Natl Acad Sci U S A (2012) 0.82
Striatal pathology underlies prion infection-mediated hyperactivity in mice. Prion (2010) 0.81
Convection-enhanced delivery of AAV2-PrPshRNA in prion-infected mice. PLoS One (2014) 0.81
Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice. Mol Ther Nucleic Acids (2012) 0.80
Therapy for prion diseases: Insights from the use of RNA interference. Prion (2009) 0.80
Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics (2013) 0.77
Identification of clinical target areas in the brainstem of prion-infected mice. Neuropathol Appl Neurobiol (2015) 0.77
The prion protein family: looking outside the central nervous system. Prion (2012) 0.77
Inhibition of the FKBP family of peptidyl prolyl isomerases induces abortive translocation and degradation of the cellular prion protein. Mol Biol Cell (2016) 0.76
Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder. PLoS One (2014) 0.76
The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion. Biomaterials (2011) 0.76
Disease-associated mutations in the prion protein impair laminin-induced process outgrowth and survival. J Biol Chem (2012) 0.76
Prion disease: experimental models and reality. Acta Neuropathol (2017) 0.75
Prion permissive pathways: extracellular matrix genes control susceptibility to prion infection. EMBO J (2014) 0.75
RTN3 Is a Novel Cold-Induced Protein and Mediates Neuroprotective Effects of RBM3. Curr Biol (2017) 0.75
Applications of RNA Interference in Schistosomiasis: Gene Function Identification and Development of New Therapies. ISRN Parasitol (2012) 0.75
Insights into prion biology: integrating a protein misfolding pathway with its cellular environment. Prion (2011) 0.75
Prion-induced neurotoxicity: Possible role for cell cycle activity and DNA damage response. World J Virol (2015) 0.75
Potential approaches for heterologous prion protein treatment of prion diseases. Prion (2016) 0.75
Prions: Beyond a Single Protein. Clin Microbiol Rev (2016) 0.75
Genetic human prion disease modelled in PrP transgenic Drosophila. Biochem J (2017) 0.75
An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein. PLoS One (2017) 0.75
Gene suppression approaches to neurodegeneration. Alzheimers Res Ther (2017) 0.75
Dual role of cellular prion protein in normal host and Alzheimer's disease. Proc Jpn Acad Ser B Phys Biol Sci (2017) 0.75
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
Mice devoid of PrP are resistant to scrapie. Cell (1993) 11.46
Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature (1992) 9.01
A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res (1988) 7.29
Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J (1996) 6.66
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63
Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science (2003) 4.57
Impaired recognition memory in rats after damage to the hippocampus. J Neurosci (2000) 4.07
Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell (1993) 2.93
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci (2005) 2.75
Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron (2007) 2.58
Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci Lett (1989) 2.48
Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet (2001) 2.36
Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J (2002) 2.26
PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration (1994) 2.21
High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med (1994) 2.18
A requirement for the immediate early gene zif268 in reconsolidation of recognition memory after retrieval. Neuron (2003) 2.08
Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur J Neurosci (2003) 2.07
No propagation of prions in mice devoid of PrP. Cell (1994) 2.02
Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther (2006) 1.72
Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci (2005) 1.53
AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol (2005) 1.29
Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol (2006) 1.27
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest (2006) 1.19
Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci (2003) 1.13
Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein. Hum Gene Ther (2007) 1.12
Differences in transductional tropism of adenoviral and lentiviral vectors in the rat brainstem. Exp Physiol (2004) 1.10
Comparison of the neuropathological characteristics of bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD) in mice. Neuropathol Appl Neurobiol (2003) 1.09
Burrowing into prion disease. Neuroreport (2001) 1.07
Efficient and specific down-regulation of prion protein expression by RNAi. Biochem Biophys Res Commun (2003) 1.01
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med (2013) 4.62
Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science (2003) 4.57
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet (2005) 4.21
An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science (2005) 3.61
Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science (2003) 3.59
Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature (2012) 3.54
Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet (2006) 3.12
BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J (2002) 2.98
Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science (2004) 2.82
Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature (2011) 2.74
Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ (2013) 2.74
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65
Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet (2011) 2.60
Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron (2007) 2.58
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol (2013) 2.42
Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain (2003) 2.42
Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature (2003) 2.31
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
A systematic review of prion therapeutics in experimental models. Brain (2006) 2.25
Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nat Neurosci (2010) 2.23
Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol (2004) 2.15
A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain (2008) 2.13
Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet (2013) 2.09
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein. Lancet (2004) 1.96
Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun (2011) 1.96
Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol (2009) 1.94
Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain (2013) 1.93
Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci (2010) 1.92
Variant CJD in an individual heterozygous for PRNP codon 129. Lancet (2009) 1.84
Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. Biochem J (2008) 1.77
Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol (2008) 1.73
Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proc Natl Acad Sci U S A (2002) 1.70
A novel prion disease associated with diarrhea and autonomic neuropathy. N Engl J Med (2013) 1.69
Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO J (2009) 1.66
PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development (2002) 1.64
Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord (2010) 1.56
A novel protective prion protein variant that colocalizes with kuru exposure. N Engl J Med (2009) 1.53
Update on human prion disease. Biochim Biophys Acta (2007) 1.46
Inherited prion disease with 4-octapeptide repeat insertion: disease requires the interaction of multiple genetic risk factors. Brain (2011) 1.45
Molecular and clinical classification of human prion disease. Br Med Bull (2003) 1.45
Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. J Biol Chem (2005) 1.42
High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain (2010) 1.42
Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol (2013) 1.41
Atypical scrapie prions from sheep and lack of disease in transgenic mice overexpressing human prion protein. Emerg Infect Dis (2013) 1.38
Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci U S A (2008) 1.37
Regional heterogeneity of cellular prion protein isoforms in the mouse brain. Brain (2003) 1.37
Subclinical prion infection. Trends Microbiol (2003) 1.36
Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Hum Mol Genet (2010) 1.35
The role of CHMP2B in frontotemporal dementia. Biochem Soc Trans (2009) 1.34
Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain (2006) 1.34
Wnt signalling inhibits neural differentiation of embryonic stem cells by controlling bone morphogenetic protein expression. Mol Cell Neurosci (2003) 1.32
Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease. Cell Metab (2013) 1.32
Identification of genetic loci affecting mouse-adapted bovine spongiform encephalopathy incubation time in mice. Neurogenetics (2002) 1.31
Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain (2006) 1.31
Subclinical prion infection in humans and animals. Br Med Bull (2003) 1.25
Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS One (2010) 1.25
Characterization of two distinct prion strains derived from bovine spongiform encephalopathy transmissions to inbred mice. J Gen Virol (2004) 1.23
An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy. Dis Model Mech (2009) 1.22
Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proc Natl Acad Sci U S A (2006) 1.22
Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. Arch Neurol (2008) 1.20
CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet (2007) 1.20
Chronic wasting disease prions are not transmissible to transgenic mice overexpressing human prion protein. J Gen Virol (2010) 1.19
White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy? Neurology (2013) 1.18
HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genet (2009) 1.18
Rational targeting for prion therapeutics. Nat Rev Neurosci (2005) 1.18
Mapping the progression of progranulin-associated frontotemporal lobar degeneration. Nat Clin Pract Neurol (2008) 1.17
Genetic variability in CLU and its association with Alzheimer's disease. PLoS One (2010) 1.16
Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. J Gen Virol (2009) 1.16
Inherited prion disease with six octapeptide repeat insertional mutation--molecular analysis of phenotypic heterogeneity. Brain (2006) 1.15
The residue 129 polymorphism in human prion protein does not confer susceptibility to Creutzfeldt-Jakob disease by altering the structure or global stability of PrPC. J Biol Chem (2004) 1.14
An enzyme-detergent method for effective prion decontamination of surgical steel. J Gen Virol (2005) 1.14
Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. EMBO J (2011) 1.13
One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. J Neuropathol Exp Neurol (2011) 1.13
Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. Hum Mol Genet (2011) 1.12